T cell responses in psoriasis and psoriatic arthritis

Autoimmunity Reviews

Volumn 14, Issue 4, 2015, Pages 286-292

  Diani, Marco ^a,b   Altomare, Gianfranco ^a,b   Reali, Eva ^a  

^a IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Antigen specific T cells; Psoriasis psoriatic arthritis genetics; Psoriasis psoriatic arthritis immunology autoimmunity; Psoriasis psoriatic arthritis inflammation; Psoriasis psoriatic arthritis pathogenesis; Self antigen cross presentation

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 22; INTERLEUKIN 23; TUMOR NECROSIS FACTOR; CYTOKINE;

AMINO ACID SEQUENCE; ANTIGEN SPECIFICITY; CD8+ T LYMPHOCYTE; CLINICAL FEATURE; DENDRITIC CELL; DISEASE ASSOCIATION; GAMMA DELTA T LYMPHOCYTE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATION; KERATINOCYTE; LYMPHOID TISSUE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; SYNOVIAL FLUID; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH22 CELL; AUTOIMMUNITY; GENETICS; IMMUNOLOGY; PATHOLOGY; SKIN;

ARTHRITIS, PSORIATIC; AUTOIMMUNITY; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; HUMANS; INFLAMMATION; KERATINOCYTES; PSORIASIS; SKIN;

EID: 84923093767     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.11.012     Document Type: Review

References (63)

1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N Engl J Med 2009, 361:496-509.
2. Levine D., Gottlieb A. Evaluation and management of psoriasis: an internist's guide. Med Clin North Am 2009, 93:1291-1303.
3. Krishnamurthy K., Walker A., Gropper C.A., Hoffman C. To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection. J Drugs Dermatol 2010, 9:241-250.
4. Naldi L., Peli L., Parazzini F., Carrel C.F. Psoriasis study group of the Italian group for epidemiological research in D: family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001, 44:433-438.
5. Raychaudhuri S.K., Maverakis E., Raychaudhuri S.P. Diagnosis and classification of psoriasis. Autoimmun Rev 2014, 13:490-495.
6. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. Lancet 2007, 370:263-271.
7. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
8. Liu Y., Krueger J.G., Bowcock A.M. Psoriasis: genetic associations and immune system changes. Genes Immun 2007, 8:1-12.
9. Bosè F., Petti L., Diani M., Moscheni C., Molteni S., Altomare A., et al. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by tNF blockade in patients with psoriasis. Am J Pathol 2013, 183:413-421.
10. Ceponis A., Kavanaugh A. Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 2010, 28:S132-S137.
11. Chandran V., Gladman D.D. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010, 12:288-294.
12. Schakel K., von Kietzell M., Hansel A., Ebling A., Schulze L., Haase M., et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity 2006, 24:767-777.
13. Vander Cruyssen B., Hoffman I.E., Zmierczak H., Van den Berghe M., Kruithof E., De Rycke L., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005, 64:1145-1149.
14. Farber E.M., Nall M.L., Watson W. Natural history of psoriasis in 61 twin pairs. Arch Dermatol 1974, 109:207-211.
15. Trembath R.C., Clough R.L., Rosbotham J.L., Jones A.B., Camp R.D., Frodsham A., et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet 1997, 6:813-820.
16. Duffin K.C., Woodcock J., Krueger G.G. Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther 2010, 23:101-113.
17. Capon F. IL36RN mutations in generalized pustular psoriasis: just the tip of the iceberg?. J Invest Dermatol 2013, 133:2503-2504.
18. Berki D.M., Mahil S.K., Burden A.D., Trembath R.C., Smith C.H., Capon F., et al. Loss of IL36RN function does not confer susceptibility to psoriasis vulgaris. J Invest Dermatol 2014, 134:271-273.
19. Villanova F., Flutter B., Tosi I., Grys K., Sreeneebus H., Perera G.K., et al. Characterization of innate lymphoid cells in human skin and blood demonstrates increase of NKp44+ ILC3 in psoriasis. J Invest Dermatol 2014, 134:984-991.
20. Anandarajah A.P., Ritchlin C.T. Pathogenesis of psoriatic arthritis. Curr Opin Rheumatol 2004, 16:338-343.
21. Nograles K.E., Brasington R.D., Bowcock A.M. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009, 5:83-91.
22. Chandran V., Bull S.B., Pellett F.J., Ayearst R., Pollock R.A., Gladman D.D. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology (Oxford) 2014, 53:233-239.
23. Lowes M.A., Suarez-Farinas M., Krueger J.G. Immunology of psoriasis. Annu Rev Immunol 2014, 32:227-255.
24. Sigurdardottir S.L., Thorleifsdottir R.H., Valdimarsson H., Johnston A. The association of sore throat and psoriasis might be explained by histologically distinctive tonsils and increased expression of skin-homing molecules by tonsil T cells. Clin Exp Immunol 2013, 174:139-151.
25. Sigurdardottir S.L., Thorleifsdottir R.H., Valdimarsson H., Johnston A. The role of the palatine tonsils in the pathogenesis and treatment of psoriasis. Br J Dermatol 2013, 168:237-242.
26. Lowes M.A., Chamian F., Abello M.V., Fuentes-Duculan J., Lin S.L., Nussbaum R., et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005, 102:19057-19062.
27. Wagner E.F., Schonthaler H.B., Guinea-Viniegra J., Tschachler E. Psoriasis: what we have learned from mouse models. Nat Rev Rheumatol 2010, 6:704-714.
28. Nestle F.O., Conrad C., Tun-Kyi A., Homey B., Gombert M., Boyman O., et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005, 202:135-143.
29. Lande R., Gregorio J., Facchinetti V., Chatterjee B., Wang Y.H., Homey B., et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007, 449:564-569.
30. Mackern-Oberti J.P., Llanos C., Vega F., Salazar-Onfray F., Riedel C.A., Bueno S.M., et al. Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases. Autoimmun Rev 2015, 14:127-139.
31. Batycka-Baran A., Maj J., Wolf R., Szepietowski J.C. The new insight into the role of antimicrobial proteins-alarmins in the immunopathogenesis of psoriasis. J Immunol Res 2014, 2014:628289.
32. Lande R., Chamilos G., Ganguly D., Demaria O., Frasca L., Durr S., et al. Cationic antimicrobial peptides in psoriatic skin cooperate to break innate tolerance to self-DNA. Eur J Immunol 2014, (in press).
33. Haider A.S., Lowes M.A., Suarez-Farinas M., Zaba L.C., Cardinale I., Khatcherian A., et al. Identification of cellular pathways of "type 1," Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008, 180:1913-1920.
34. Zaba L.C., Cardinale I., Gilleaudeau P., Sullivan-Whalen M., Suarez-Farinas M., Fuentes-Duculan J., et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007, 204:3183-3194.
35. Zaba L.C., Fuentes-Duculan J., Eungdamrong N.J., Abello M.V., Novitskaya I., Pierson K.C., et al. Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol 2009, 129:79-88.
36. Lowes M.A., Russell C.B., Martin D.A., Towne J.E., Krueger J.G. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 2013, 34:174-181.
37. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., et al. Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 2011, 35:596-610.
38. Russell S.E., Stefanska A.M., Kubica M., Horan R.M., Mantovani A., Garlanda C., et al. Toll IL-1R8/single Ig IL-1-related receptor regulates psoriasiform inflammation through direct inhibition of innate IL-17A expression by gammadelta T cells. J Immunol 2013, 191:3337-3346.
39. Teunissen M.B., Munneke J.M., Bernink J.H., Spuls P.I., Res P.C., Te Velde A., et al. Composition of innate lymphoid cell subsets in the human skin: enrichment of NCR(+) ILC3 in lesional skin and blood of psoriasis patients. J Invest Dermatol 2014, 134:2351-2360.
40. Girardi M. Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 2006, 126:25-31.
41. Conigliaro P., Scrivo R., Valesini G., Perricone R. Emerging role for NK cells in the pathogenesis of inflammatory arthropathies. Autoimmun Rev 2011, 10:577-581.
42. Di Cesare A., Di Meglio P., Nestle F.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol 2009, 129:1339-1350.
43. Lai Y., Li D., Li C., Muehleisen B., Radek K.A., Park H.J., et al. The antimicrobial protein REG3A regulates keratinocyte proliferation and differentiation after skin injury. Immunity 2012, 37:74-84.
44. Zaba L.C., Suarez-Farinas M., Fuentes-Duculan J., Nograles K.E., Guttman-Yassky E., Cardinale I., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009, 124. [1022-10 e1-395].
45. Kryczek I., Bruce A.T., Gudjonsson J.E., Johnston A., Aphale A., Vatan L., et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
46. Harden J.L., Johnson-Huang L.M., Chamian M.F., Lee E., Pearce T., Leonardi C.L., et al. Humanized anti-IFN-gamma (HuZAF) in the treatment of psoriasis. J Allergy Clin Immunol 2014, (in press).
47. Chimenti M.S., Ballanti E., Perricone C., Cipriani P., Giacomelli R., Perricone R. Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. Autoimmun Rev 2013, 12:599-606.
48. Suzuki E., Mellins E.D., Gershwin M.E., Nestle F.O., Adamopoulos I.E. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev 2014, 13:496-502.
49. Anandarajah A.P., Schwarz E.M., Totterman S., Monu J., Feng C.Y., Shao T., et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. Ann Rheum Dis 2008, 67:296-301.
50. Teunissen M.B., Yeremenko N.G., Baeten D.L., Chielie S., Spuls P.I., de Rie M.A., et al. The IL-17A-producing CD8(+) T-cell population in psoriatic lesional skin comprises mucosa-associated invariant T cells and conventional T cells. J Invest Dermatol 2014, 134:2898-2907.
51. Boyman O., Conrad C., Tonel G., Gilliet M., Nestle F.O. The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol 2007, 28:51-57.
52. Conrad C., Boyman O., Tonel G., Tun-Kyi A., Laggner U., de Fougerolles A., et al. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat Med 2007, 13:836-842.
53. Prinz J.C. Disease mimicry-a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry?. Autoimmun Rev 2004, 3:10-15.
54. Menon B., Gullick N.J., Walter G.J., Rajasekhar M., Garrood T., Evans H.G., et al. Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheumatol 2014, 66:1272-1281.
55. Bosè F., Capsoni F., Molteni S., Raeli L., Diani M., Altomare A., et al. Differential expression of interleukin-2 by anti-CD3-stimulated peripheral blood mononuclear cells in patients with psoriatic arthritis and patients with cutaneous psoriasis. Clin Exp Dermatol 2014, 39:385-390.
56. Johnston A., Gudjonsson J.E., Sigmundsdottir H., Love T.J., Valdimarsson H. Peripheral blood T cell responses to keratin peptides that share sequences with streptococcal M proteins are largely restricted to skin-homing CD8(+) T cells. Clin Exp Immunol 2004, 138:83-93.
57. Gudjonsson J.E., Thorarinsson A.M., Sigurgeirsson B., Kristinsson K.G., Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003, 149:530-534.
58. McFadden J., Valdimarsson H., Fry L. Cross-reactivity between streptococcal M surface antigen and human skin. Br J Dermatol 1991, 125:443-447.
59. Valdimarsson H., Thorleifsdottir R.H., Sigurdardottir S.L., Gudjonsson J.E., Johnston A. Psoriasis-as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009, 30:494-501.
60. Sigmundsdottir H., Sigurgeirsson B., Troye-Blomberg M., Good M.F., Valdimarsson H., Jonsdottir I. Circulating T cells of patients with active psoriasis respond to streptococcal M-peptides sharing sequences with human epidermal keratins. Scand J Immunol 1997, 45:688-697.
61. Valdimarsson H., Sigmundsdottir H., Jonsdottir I. Is psoriasis induced by streptococcal superantigens and maintained by M-protein-specific T cells that cross-react with keratin?. Clin Exp Immunol 1997, 107(Suppl. 1):21-24.
62. Valdimarsson H., Baker B.S., Jonsdottir I., Powles A., Fry L. Psoriasis: a T-cell-mediated autoimmune disease induced by streptococcal superantigens?. Immunol Today 1995, 16:145-149.
63. Curran S.A., FitzGerald O.M., Costello P.J., Selby J.M., Kane D.J., Bresnihan B., et al. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens. J Immunol 2004, 172:1935-1944.